Kaiser Family Foundation Looks AtÂ Views On The U.S. Role In Global Health As a follow-up to a survey conducted in May 2009, this poll examines Americans’ attitudes toward U.S. global health investments and priorities. Some key findings include: the majority of Americans support maintaining (32%) or increasing (34%) spending on…
“Two years after some $22 million in donor funds were pumped into malaria control along the Cambodia-Thailand border to fight off suspected resistance to treatment, health workers say the battle is not over,” IRIN reports, adding, “The government reported 103,000 malaria infections and 151 deaths nationwide in 2010. A year later, 85,000 reported infections led to 93 deaths — a 38-percent decline in mortality.” “‘If you take your foot off the â€¦ [accelerator] we can lose everything we have done in the past two to three years,’ Steven Bjorge, anti-malaria team leader in Cambodia for the [WHO], told IRIN in February 2012,” the news service writes.
“Drug-resistant strains of gonorrhea have spread to countries across the world, the U.N. health agency said on Wednesday, and millions of patients may run out of treatment options unless doctors catch and treat cases earlier,” Reuters reports (Kelland, 6/6). “Already several countries, including Australia, France, Japan, Norway, Sweden and the United Kingdom are reporting cases of resistance to cephalosporin antibiotics — the last treatment option against gonorrhea,” a WHO press release states (6/6).
With incentives to find new antibiotics signed into U.S. law last month, “multiple players are vying for the lead in the [multi-drug resistant tuberculosis (MDR-TB)] drug development niche,” Nature Medicine reports. “The fifth reauthorization of the U.S. Prescription Drug User Fee Act (PDUFA), signed into law on 9 July, includes a subsection called the Generating Antibiotic Incentives Now (GAIN) Act that aims to spur development of antibiotics for drug-resistant bacteria, including MDR-TB,” the news service writes, noting, “Drug makers that ask for approval of medicines to treat these pathogens will receive priority review, as well as five additional years of market exclusivity and fast-track status.” Currently, MDR-TB treatment “involves a bevy of regular tuberculosis medicines that, in many cases, must be administered for as long as two years or more … [and] don’t always work,” Nature Medicine states, adding, “The hope is that new medicines will shorten treatment times and improve cure rates.” The article discusses several medicines that are in different phases of research (Willyard, 8/6).
As more bacteria become resistant to antibiotics, “common infections could become deadly, according to” WHO Director-General Margaret Chan, who spoke on Wednesday at a conference titled “Combating Antimicrobial Resistance: Time for Action” in Copenhagen, ABC News reports. “‘Some experts say we are moving back to the pre-antibiotic era. No. This will be a post-antibiotic era. In terms of new replacement antibiotics, the pipeline is virtually dry,’ said Chan. ‘A post-antibiotic era means, in effect, an end to modern medicine as we know it. Things as common as strep throat or a child’s scratched knee could once again kill,’” the news service notes (Moisse, 3/16).
On Tuesday at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, scientists and global health experts focused on malaria eradication, Agence France-Presse reports. “Key among the strategies … is the development of an effective anti-malaria vaccine, a project scientists have been researching since the late 80s. … RTS,S is the most clinically advanced malaria vaccine so far, according to the Malaria Vaccine Initiative,” the news service writes (11/3).
Study Shows Prevalence Of Drug-Resistant HIV Strains In Uganda Rising, Among Highest In Sub-Saharan Africa
“The prevalence of drug-resistant HIV strains in Uganda has risen from 8.6 percent to 12 percent in the last five years, one of the highest rates in sub-Saharan Africa, according to a recent study,” PlusNews reports. “The PharmAccess African Studies to Evaluate Resistance (PASER) monitoring cohort study report for 2008-2012” — “which was based on results from the capital, Kampala, the western town of Fort Portal, and the eastern town of Mbale” — “found that the prevalence of transmitted drug resistance among people who have never taken life-prolonging antiretroviral (ARV) medication was substantially higher in Uganda” than in Kenya, Nigeria, South Africa, Zambia, and Zimbabwe, the news service writes.
“Malaria-carrying mosquitoes in Africa and India are becoming resistant to insecticides, putting millions of lives at greater risk and threatening eradication efforts, health experts said on Tuesday,” Reuters reports (Kelland, 5/15). Experts fear resistance “could reverse the recent drop in malaria mortality credited to insecticide spraying in the home and coating of bed nets, which save about 220,000 children’s lives each year, according to the WHO,” Nature writes, adding, “Insecticide resistance could also result in as many as 26 million further cases a year, the organization predicts, costing an extra $30 million to $60 million annually for tests and medicines” (Maxmen, 5/15).
The Globe and Mail reports on “a massive resurgence of malaria [in the Democratic Republic of the Congo] that has baffled scientists and raised doubts about the global fight against the deadly scourge.” “Malaria is already the single biggest killer in Congo, with nearly 200,000 people dying annually, and now the trend is worsening,” the newspaper writes, noting that “the number of malaria patients has soared by a stunning 250 percent … since 2009,” according to data from Medecins Sans Frontieres (MSF).
Nature examines efforts to combat antibiotic resistance in India, writing, “Antibiotic resistance is a problem worldwide, but is particularly worrying in India, where hospital standards are inconsistent and antibiotics are readily available over the counter at pharmacies.” The magazine highlights “India’s first joint medical-society meeting on antibiotic resistance, held on 24 August in Chennai,” noting, “The symposium is part of an ongoing campaign by Indian clinicians for a national policy to curb misuse of these vital drugs.” It continues, “Last week, physicians moved a step closer to their goal when India’s drug regulators announced a plan that would put tight restrictions on the sale of antibiotics.”